Drug Trial Radar · NCT00634400
Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative)
Last checked: Nov 20, 2026Latest source record: Jan 25, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6,268
Planned (sponsor's estimate)
Start
Mar 1999
Primary completion
May 2003
Study completion May 2003
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Mar 13, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
Summary
As written by the sponsor on the registry.
A study to evaluate the effect of Atacand on patients with heart failure with depressed left ventricular function
Conditions
- Congestive Heart Failure
Interventions
CandesartanDrug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cardiovascular mortality or hospitalisation due to congestive heart failureTime frame: 2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.